Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.61 |
| ▸ | ITGAV | P06756 | 6/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.61 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.61 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.61 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.55 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519784 | 1.00 | ITGB3 (0.61) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7146704 | 0.81 | MEN1 (0.56) | SUCNR1 | |
| SCHEMBL7146701 | 0.81 | MEN1 (0.56) | SUCNR1 | |
| SCHEMBL24920672 | 0.80 | CA12 (0.67) | SUCNR1CA12CA1CA2CA9 | |
| SCHEMBL7136733 | 0.80 | MEN1 (0.51) | ITGB3SUCNR1ITGA2B | |
| SCHEMBL7136737 | 0.80 | MEN1 (0.51) | ITGB3SUCNR1ITGA2B | |
| SCHEMBL14811632 | 0.80 | CA12 (0.64) | ITGB3SUCNR1CA12CA1CA2 | |
| SCHEMBL6715357 | 0.78 | CA12 (0.50) | ITGB3SUCNR1CA12CA1CA2 | |
| SCHEMBL6715354 | 0.78 | CA12 (0.50) | ITGB3SUCNR1CA12CA1CA2 | |
| SCHEMBL7291406 | 0.78 | ITGB3 (0.82) | ITGB3ITGB1SUCNR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ITGB3 82/4885ITGAV 146/4885ITGB1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.